200, 82 Richmond Street East
Toronto, ON M5C 1P1
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
|Mr. Jackie Peter Burnett||Pres, CEO & Chairman||341.61k||N/A||N/A|
|Mr. Guillermo Martin Delmonte||COO, Interim CFO & Corp. Sec.||238.1k||N/A||N/A|
RAMM Pharma Corp. engages in the research and development, production, and sale of cannabinoid pharmaceutical formulations, pharmaceuticals, cosmetics, nutraceutical products, and resale of medical supplies products in Canada and internationally. It offers Epifractán, a cannabinoid pharmaceutical drug; XALEX 10, a prescription pharmaceutical formulation for the treatment of refractory epilepsy; and NettaLife, a cannabis-based product for pets. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
RAMM Pharma Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.